{\rtf1\ansi\deff0\deftab360

{\fonttbl
{\f0\fswiss\fcharset0 Arial}
{\f1\froman\fcharset0 Times New Roman}
{\f2\fswiss\fcharset0 Verdana}
{\f3\froman\fcharset2 Symbol}
}

{\colortbl;
\red0\green0\blue0;
}

{\info
{\author Biblio 7.x}{\operator }{\title Biblio RTF Export}}

\f1\fs24
\paperw11907\paperh16839
\pgncont\pgndec\pgnstarts1\pgnrestart
Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades ICalvo, Fischbach M, Alcala JOrozco, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace C, Alessio M, Quartier P, Cortis E, Eberhard A, Simonini G, Lemelle I, Chalom ECandell, Sigal LH, Block A, Covucci A, Nys M, Martini A, Giannini EH. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2010;62(11):1542-51.\par \par Vilca I, Munitis PGarcia, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, H\'e4fner R, Hofer M, Ozen S, Huemer C, Bae SCheol, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HIko, Gamir MLuz, Magnusson B, Dressler F, Uziel Y, van Rossum MAJ, Hollingworth P, Cawkwell G, Martini A, Ruperto N. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010;69(8):1479-83.\par \par }